- testing |
| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 30 May 2025 | 21 May 2025 |
| Astrazeneca Pharma India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve 1. The audited financial results of the Company for the quarter and year ended March 31 2025. 2. To recommend Dividend if any on the equity shares of the Company for the financial year 2024-25. We also inform you that the Trading Window remains closed for all Designated Persons from March 16 2025 to June 1 2025 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. Recommendation of Dividend for the Financial Year 2024-25 (As Per BSE Announcement Dated on :30.05.2025) | ||
| Board Meeting | 11 Feb 2025 | 20 Jan 2025 |
| Quarterly Results ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 ,inter alia, to consider and approve This is to inform that the Meeting of the Board of Directors of AstraZeneca Pharma India Limited will be held on Tuesday, February 11, 2025 inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024. We would also like to inform you that the Trading Window remains closed for all Designated Persons, from December 16, 2024 to February 13, 2025 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. At the Board meeting of the Company held on Tuesday, February 11, 2025, the Board of Directors considered and approved the unaudited financial results of the Company for the quarter ended December 31, 2024. The said unaudited financial results together with the Limited Review Report of the Statutory Auditors dated December 31, 2024 are enclosed herewith. (As Per BSE Announcement dated on 11.02.2025) Please find the enclosed intimation of the Company as per the captioned subject. (As per BSE Announcement Dated on 03/03/2025) | ||
| Board Meeting | 13 Nov 2024 | 25 Oct 2024 |
| ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2024. Please find the enclosed financial results for the quarter and half year ended September 30, 2024. (As Per BSE Announcement dated on 13.11.2024) | ||
| Board Meeting | 8 Aug 2024 | 24 Jul 2024 |
| ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve The Unaudited Financial Results of the Company for the quarter ended June 30 2024. We would also like to inform you that the Trading Window remains closed for all Designated Persons from June 16 2024 to August 10 2024 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. We request you to please take the same on record. Please find the enclosed financial results for the quarter ended June 30, 2024. (As per BSE Announcement Dated on 08/08/2024) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.